GF-CART01

N/A

Report date: 2024/11/26 20:00:06

Base Information

Drug NameGF-CART01
Drug Alias NameGF-CART01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenomeFrontier Therapeutics TW Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGenomeFrontier Therapeutics TW Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A